CompletedNCT01685619

AML-MDS Novel Prognostic Tests Clinical Study

Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nova Scotia Health Authority
Principal Investigator
Stephen Couban, M.D.
Nova Scotia Health Authority
Enrollment
11 enrolled
Eligibility
18 years · All sexes
Timeline
20122018

Study locations (6)

Collaborators

Terry Fox Research Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01685619 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

← Back to all trials